Biosimilars

Biosimilars

Biologics have transformed the treatment of many life-limiting diseases, but with the significant burden of disease, healthcare systems are continuing to face a financial challenge to meet the needs of patients. The utilization of high-quality, lower-cost biosimilars can improve the sustainability of healthcare systems, providing the potential for more patients to benefit from biological medicines. We are dedicated to improving the lives of patients by promoting the use of biosimilars to expand overall treatment options and contribute to the quality and sustainability of the US healthcare system.

Latest Articles on Biosimilars

What Are Biosimilars?

A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.

Boehringer Ingelheim Fremont, Inc.

Article

Boehringer Ingelheim Fremont, Inc.

Based in the San Francisco Bay Area, Boehringer Ingelheim’s only US Biopharmaceutical manufacturing site represents the company’s history as a biotechnology pioneer.

Bringing Value to the Healthcare Community

Article

Bringing Value to the Healthcare Community

Our fundamental mission is to make the lives of patients better. We listen, we take the time to understand, and through meaningful and impactful partnerships, we aim to create a lasting difference.